Study Evaluating Enbrel in Patients With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the incidence of adverse events for patients with rheumatoid arthritis treated with Enbrel under usual care settings. In addition, differences in injection site reactions based on whether health care professionals or patients administer Enbrel will be assessed and evaluated.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Proven diagnosis of rheumatoid arthritis

Exclusion Criteria:

• Contraindications according to Summary of Product Characteristic (SmPC)of Enbrel® the following points will prevent or restrict participation:

• Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®

• Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localized infections

• Patients with sepsis or risk of sepsis should not be treated